



24 August 2018

ASX ANNOUNCEMENT

L-Dex[®] Suggested as a New Standard of Care

Brisbane, Australia - ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to announce the completion of the first in a series of educational seminars to be presented by the Principal Investigator of the PREVENT trial – “Removing the Mystery Around Bioimpedance – Moving Towards a New Standard of Care”. The presentation was broadcast live online at 8.00am PDT on 23 August 2018.

The purpose of the seminar was to present BIS and the L-Dex[®] technology as the new standard of care for cancer survivors at risk of developing lymphoedema.

This is the beginning of a series of seminars that will take place across the US and Australia to embolden clinicians to adopt BIS as the standard of care in the early detection of lymphoedema. The Principal Investigator encouraged patients to discuss BIS with their healthcare providers for use in the clinic and to contact insurance payors to ask for coverage for its use as the technology is supported by research.

The presentation included top-line results from the interim analysis of the PREVENT trial and demonstrated that L-Dex[®] technology was seamlessly integrated into some of the busiest breast cancer clinics in the world.

“Millions of people needlessly suffer from lymphoedema caused by cancer or cancer treatment. Early identification with BIS should be integral in the management of every patient who is at risk so that consequences can be minimised or eliminated for these patients,” said Richard Carreon, Managing Director and CEO of ImpediMed.

A link to the presentation can be found here:
<https://livestream.com/LymphaticRF/ridner>

Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

For personal use only

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.